ArticleAnnals of surgical oncology2026
Prognostic Role of Pretreatment Nutritional and Inflammatory Status in Unresectable Metastatic Colorectal Cancer: Supplementary Analysis of JCOG1007.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundPrimary tumor resection (PTR) is not routinely recommended for asymptomatic patients with unresectable stage IV colorectal cancer, based on the results from the Japan Clinical Oncology Group (JCOG)-1007 trial, which showed no survival benefit over upfront chemotherapy. However, host-related factors such as nutritional status and systemic inflammation may impact on treatment outcomes. We conducted a supplementary analysis of JCOG1007 to evaluate whether pretreatment modified Glasgow Prognostic Score (mGPS), albumin, and C-reactive protein were associated with differential outcomes after upfront PTR.
methodsPatients registered in JCOG1007 were stratified according to pretreatment mGPS (0, 1, 2), albumin (<3.5 vs. ≥3.5 g/dL), and C-reactive protein (≤1.0 vs. >1.0 mg/dL). Overall survival and progression-free survival (PFS) were assessed using Kaplan-Meier analysis and Cox proportional hazards models. Univariable and multivariable analyses were performed within each subgroup.
resultsAmong 165 patients enrolled in JCOG1007, 154 patients without missing data were included for analysis. Patients with impaired host status, such as mGPS 2 and hypoalbuminemia, tended to have shorter overall survival and PFS after PTR than after chemotherapy alone, whereas no apparent differences were observed in other subgroups. In the mGPS 2 subgroup, PTR remained independently associated with worse PFS in multivariable analysis (hazard ratio 3.561; 95% confidence interval 1.005-12.621; P = 0.049), whereas a similar trend was observed in patients with hypoalbuminemia.
conclusionsPretreatment nutritional and inflammatory status did not identify a patient population that may benefit from PTR. These findings further support avoiding routine PTR, regardless of host status.
Indexed as
Identifiers
42766270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.